8-K: Autonomix Medical Announces Positive Preliminary Results in Pancreatic Cancer Pain Trial

Autonomix Medical reports positive preliminary results from its human clinical trial, showing significant pain reduction in pancreatic cancer patients using transvascular radiofrequency ablation.

Summary

• Autonomix Medical announced positive preliminary results from the first five lead-in patients in their proof-of-concept human clinical trial.
• The trial is evaluating the safety and effectiveness of transvascular energy delivery to ablate nerves and reduce pain in pancreatic cancer patients.
• The first five patients completed the procedure without immediate complications or significant adverse events.
• 60% of the patients experienced a mean pain reduction of 6.33 on the VAS pain scale at 7 days post-procedure, moving from a baseline of 8.0 to 1.67.
• This responder group also reported a mean 78% improvement in quality of health and a 45% improvement in quality of life at 7 days post-procedure.
• The trial remains on track to complete enrollment by the end of 2024.
• The company's catheter-based microchip sensing array was not used in this trial but will be evaluated in future studies.
• The primary objective of the trial is to assess the success rate of ablating relevant nerves to mitigate pain using radiofrequency ablation.
• Secondary objectives include assessing adverse events, changes in pain levels, and changes in quality of life.
• The company has amended the trial protocol to gather additional information on tumor encroachment and other bio-measurements.
• An additional 20 subjects will be enrolled in the trial for formal data analysis.

Sentiment

Score: 8

Explanation: The document presents positive preliminary results from a clinical trial, indicating potential for a new treatment for pancreatic cancer pain. The high response rate and improvements in quality of life are encouraging, although the study is still in early stages and there are some limitations.

Positives

• The initial results show a significant reduction in pain for a subset of patients with pancreatic cancer.
• The procedure was completed without immediate complications or significant adverse events.
• Patients reported a substantial improvement in their quality of health and quality of life.
• The trial is progressing as planned and is on track to complete enrollment by the end of 2024.
• The company is gathering additional data to optimize the procedure and improve outcomes.

Negatives

• The first five patients were lead-in patients and their data will not be included in the final analysis of the trial objectives.
• Two patients in the study have passed away due to their disease, although these events were expected and not related to the procedure.
• Not all patients responded to the treatment, with some showing no improvement or worsening of pain scores.
• The catheter access point appears to impact the effectiveness of the treatment, with femoral access showing better results than brachial access.

Risks

• The trial is still in its early stages, and the results are preliminary.
• The technology is investigational and has not yet been cleared for marketing in the US.
• The company is relying on a small sample size of patients for these initial results.
• The success of the treatment may depend on the catheter access point and the ability to target the correct nerves.
• The underlying disease progression in patients with pancreatic cancer may impact the long-term effectiveness of the treatment.

Future Outlook

Autonomix plans to continue enrolling patients in the clinical trial and expects to complete enrollment by the end of 2024. The company also plans to evaluate its catheter-based microchip sensing array in future studies to improve the targeting and effectiveness of the treatment. They are also planning follow-on indications pending the results of the initial data.

Management Comments

• We are very pleased with these initial positive results, which confirm our ability to treat this historically difficult-to-treat cancer pain with catheter-based transvascular RF ablation.
• We are extraordinarily pleased with the positive outcome this procedure is having on responding patients and the relief they are experiencing from the difficulty of end-stage pancreatic cancer.
• We believe that in future studies and with our catheter-based microchip sensing array, we may be able to improve on the level of responders.

Industry Context

This announcement is significant in the context of the medical device industry, particularly for companies focused on pain management and cancer treatment. The positive results suggest a potential new approach to treating pancreatic cancer pain, which is a significant unmet medical need. The company's technology could offer an alternative to traditional methods like opioids and invasive injections.

Comparison to Industry Standards

• Current treatments for pancreatic cancer pain often rely on opioids, which have limited effectiveness and significant side effects, or invasive ethanol injections, which can be risky.
• Autonomix's approach of using transvascular radiofrequency ablation is a novel method that aims to directly target the nerves causing pain.
• The reported 6.33 point reduction in pain on the VAS scale for responders is a significant improvement compared to the limited relief often provided by current methods.
• Companies like Boston Scientific and Medtronic offer pain management solutions, but Autonomix's technology is unique in its approach to targeting nerves through a transvascular method.
• The use of a catheter-based microchip sensing array in future studies could further differentiate Autonomix's technology from existing solutions.

Stakeholder Impact

• Shareholders may view the positive results as a positive development for the company's future prospects.
• Patients with pancreatic cancer may benefit from a new treatment option for pain management.
• Employees may be motivated by the positive results and the potential impact of their work.
• The medical community may be interested in the new technology and its potential applications.

Next Steps

• Autonomix will continue to enroll patients in the clinical trial.
• The company will gather additional data on tumor encroachment and other bio-measurements.
• Autonomix will evaluate its catheter-based microchip sensing array in future studies.
• The company plans to complete enrollment in the PoC human clinical trial by year-end 2024.

Key Dates

Keywords

pancreatic cancer, pain management, radiofrequency ablation, transvascular, clinical trial, medical device, neurology, VAS pain scale, quality of life, nerve ablation